Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
|Articles|April 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Helicobacter pylori Eradication and Screening
- Volume 4
- Issue 5 Suppl
Participating Faculty
Advertisement
Articles in this issue
over 28 years ago
The Impact of H Pylori Eradication on Your Pharmacy Budgetover 28 years ago
Overview of H pylori in Peptic Ulcer Diseaseover 28 years ago
Clinical Issues and Cost Effectiveness of Treating H pyloriover 28 years ago
Current Issues in H pylori Eradicationover 28 years ago
CPE Quizover 28 years ago
Selected Abstractsover 28 years ago
BibliographyAdvertisement
Related to this article
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
The Omaha-based practice will hand its inbound faxes and document management to artificial intelligence (AI) agents, with outside records retrieval to follow.
Advertisement
Advertisement
Trending on AJMC
1
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
2
CMS Moves TIC Reporting to Quarterly, Sets Drug File Timeline
3
5 Things to Know if Retatrutide Is Classified as a Biologic
4
Will Cancer Care Come Home by 2030? PCOC Panelists Differ on Strategy
5